CU20170099A7 - Terapias de combinación para el tratamiento de cánceres - Google Patents

Terapias de combinación para el tratamiento de cánceres

Info

Publication number
CU20170099A7
CU20170099A7 CUP2017000099A CU20170099A CU20170099A7 CU 20170099 A7 CU20170099 A7 CU 20170099A7 CU P2017000099 A CUP2017000099 A CU P2017000099A CU 20170099 A CU20170099 A CU 20170099A CU 20170099 A7 CU20170099 A7 CU 20170099A7
Authority
CU
Cuba
Prior art keywords
cancer treatment
combination therapies
methods
entospletinib
navitoclax
Prior art date
Application number
CUP2017000099A
Other languages
English (en)
Inventor
Paolo Julie A Di
Randall Mark Jones
Daniel B Tumas
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55398445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20170099(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CU20170099A7 publication Critical patent/CU20170099A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Se proporcionan en el presente documento métodos que se relacionan con la estrategia<br /> terapéutica para el tratamiento del cáncer, incluyendo malignidades hematológicas. En particular, los<br /> métodos incluyen la administración de entospletinib y un inhibidor de Bcl-2, tal como venetoclax,<br /> navitoclax y ABT-737.<br />  </p>
CUP2017000099A 2015-02-03 2016-01-29 Terapias de combinación para el tratamiento de cánceres CU20170099A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562111604P 2015-02-03 2015-02-03
PCT/US2016/015727 WO2016126552A1 (en) 2015-02-03 2016-01-29 Combination therapies for treating cancers

Publications (1)

Publication Number Publication Date
CU20170099A7 true CU20170099A7 (es) 2018-03-13

Family

ID=55398445

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000099A CU20170099A7 (es) 2015-02-03 2016-01-29 Terapias de combinación para el tratamiento de cánceres

Country Status (25)

Country Link
US (2) US20180117052A1 (es)
EP (1) EP3253385A1 (es)
JP (1) JP2018503653A (es)
KR (1) KR20170104616A (es)
CN (1) CN107205992A (es)
AU (1) AU2016215643A1 (es)
BR (1) BR112017016019A2 (es)
CA (1) CA2974828A1 (es)
CL (1) CL2017001943A1 (es)
CO (1) CO2017007662A2 (es)
CR (1) CR20170352A (es)
CU (1) CU20170099A7 (es)
EA (1) EA201791516A1 (es)
EC (1) ECSP17048849A (es)
GT (1) GT201700167A (es)
IL (1) IL253573A0 (es)
MA (1) MA41449A (es)
MD (1) MD20170073A2 (es)
MX (1) MX2017009724A (es)
PE (1) PE20171241A1 (es)
PH (1) PH12017550063A1 (es)
SG (1) SG11201706107SA (es)
SV (1) SV2017005489A (es)
TW (1) TW201639573A (es)
WO (1) WO2016126552A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120121A1 (es) 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 다형체
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
KR20160090903A (ko) 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2017325844A1 (en) 2016-09-14 2019-03-07 Gilead Sciences, Inc. SYK inhibitors
WO2018049634A1 (zh) * 2016-09-14 2018-03-22 杭州领业医药科技有限公司 Abt-199加成盐及其晶型、其制备方法和药物组合物
JP2020517704A (ja) * 2017-04-28 2020-06-18 アクティニウム ファーマシューティカルズ インコーポレイテッド α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法
EP3672974A1 (en) 2017-08-25 2020-07-01 Gilead Sciences, Inc. Polymorphs of syk inhibitors
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
TWI777321B (zh) 2019-12-04 2022-09-11 大陸商蘇州亞盛藥業有限公司 藥物組合及其用途
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
US20250281510A1 (en) * 2021-04-05 2025-09-11 Pinotbio, Inc. Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax
EP4473966A4 (en) * 2022-02-02 2026-01-21 Ono Pharmaceutical Co CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
PL2716157T3 (pl) * 2008-12-08 2017-06-30 Gilead Connecticut, Inc. Imidazopirazynowe inhibitory Syk
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
BR112012006252A2 (pt) 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
EP2608809B1 (en) 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
HK1201065A1 (en) 2011-10-04 2015-08-21 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
AU2013302617A1 (en) * 2012-08-14 2015-02-05 Gilead Calistoga Llc Combination therapies for treating cancer
HK1212240A1 (en) * 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
WO2014047624A1 (en) 2012-09-24 2014-03-27 Gilead Sciences, Inc. Anti-ddr1 antibodies
AU2013364068B2 (en) 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
PL3008053T3 (pl) 2013-06-14 2018-08-31 Gilead Calistoga Llc Inhibitory 3-kinazy fosfatydyloinozytolu
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 다형체
PE20160605A1 (es) * 2013-07-30 2016-07-20 Gilead Connecticut Inc Formulaciones de inhibidores de la syk

Also Published As

Publication number Publication date
SG11201706107SA (en) 2017-08-30
MA41449A (fr) 2017-12-12
CN107205992A (zh) 2017-09-26
EA201791516A1 (ru) 2018-01-31
JP2018503653A (ja) 2018-02-08
PH12017550063A1 (en) 2018-02-05
KR20170104616A (ko) 2017-09-15
CO2017007662A2 (es) 2017-10-20
CL2017001943A1 (es) 2018-03-02
MX2017009724A (es) 2017-11-17
SV2017005489A (es) 2017-10-17
AU2016215643A1 (en) 2017-08-10
MD20170073A2 (ro) 2018-02-28
GT201700167A (es) 2017-11-02
CR20170352A (es) 2017-09-29
WO2016126552A1 (en) 2016-08-11
US20160220573A1 (en) 2016-08-04
EP3253385A1 (en) 2017-12-13
PE20171241A1 (es) 2017-08-24
US20180117052A1 (en) 2018-05-03
IL253573A0 (en) 2017-09-28
ECSP17048849A (es) 2017-10-31
BR112017016019A2 (pt) 2018-03-20
TW201639573A (zh) 2016-11-16
CA2974828A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
CU20170099A7 (es) Terapias de combinación para el tratamiento de cánceres
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
NI201900019A (es) Inhibidores de procesos metabólicos celulares
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX367389B (es) Compuestos y sus metodos de empleo.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2020001550A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
UY36075A (es) Derivados de tubulisina
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.